Development of an improved biophotonic system for a novel cancer detection/monitoring blood test

开发用于新型癌症检测/监测血液测试的改进生物光子系统

• 批准号: 131964
• 金额: $ 2.94万
• 依托单位: OXFORD MEDISTRESS LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=131964
• 关键词: Development; improved; biophotonic; system; novel

Affecting one in three people over the course of their lifetimes, cancer represents a significant burden to healthcare systems around the world, costing the UK economy £11 billion annually. Oxford MediStress, an Oxford University spinout company, has recently developed a new fingerprick blood test that allows the quantitative assessment of a key component of the immune system by evaluating the vitality of white blood cells in a rapid, easy-to-use format. The Company believes this technology holds considerable promise to provide an early indication of cancer, given the way it measures immune function. It also has the potential to become an important new tool with which doctors can monitor cancer progression. However, a key optical component in the system is quite costly, meaning the system is too expensive to be marketed to the general public currently. In this project the team will evaluate alternative optical components that promise to the job just as well at a fraction of the cost. A key output of the project will be demonstration of a prototype that can perform the test at a substantially lower cost.

癌症影响着三分之一的人的一生，给世界各地的医疗系统带来了巨大的负担，每年给英国经济造成110亿英镑的损失。牛津大学的分支公司牛津医疗公司最近开发了一种新的指纹抽血测试，通过以快速、易于使用的格式评估白细胞的活力，可以对免疫系统的关键组成部分进行定量评估。该公司认为，鉴于这项技术测量免疫功能的方式，它有相当大的希望提供癌症的早期迹象。它还有可能成为医生监测癌症进展的重要新工具。然而，该系统中的一个关键光学部件相当昂贵，这意味着该系统目前太贵了，无法向普通公众销售。在这个项目中，团队将评估替代的光学组件，这些组件的成本只有很小的一部分。该项目的一个关键成果将是展示一种能够以低得多的成本进行测试的原型。